List of Excipients in Branded Drug ARTICAINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-101	SODIUM CHLORIDE
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-101	SODIUM HYDROXIDE
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-101	SODIUM METABISULFITE
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-101	WATER
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-102	SODIUM CHLORIDE
NDC Inc	ARTICAINE	articaine hydrochloride and epinephrine	43128-102	SODIUM HYDROXIDE

Articaine Excipient Strategy and Commercial Opportunities

Last updated: August 19, 2026

Articaine is a mature dental local anesthetic with limited active-ingredient patent protection and substantial formulation opportunity. The commercial focus is shifting from articaine hydrochloride itself to cartridge stability, sulfite reduction, epinephrine preservation, packaging, differentiated concentrations, and workflow improvements for dental practitioners.

The leading formulation is a sterile aqueous injection containing 4% articaine hydrochloride with epinephrine at either 1:100,000 or 1:200,000. The principal excipients are sodium chloride, sodium metabisulfite, water for injection, and pH-adjusting agents. The most commercially relevant formulation risks are epinephrine oxidation, sulfite sensitivity, container compatibility, light exposure, and dose-volume constraints in dental cartridges.[1]

What is the formulation profile of articaine?

Articaine hydrochloride is a highly water-soluble local anesthetic supplied primarily as a 4% injectable solution for dental anesthesia. Unlike lidocaine, articaine contains both an amide linkage and an additional ester group. It is rapidly hydrolyzed by plasma esterases, producing an inactive metabolite.[2]

Attribute	Commercially relevant profile
Active ingredient	Articaine hydrochloride
Common strength	4% w/v, equivalent to 40 mg/mL
Vasoconstrictor	Epinephrine, usually 1:100,000 or 1:200,000
Primary dosage form	Sterile dental cartridge injection
Typical cartridge volume	1.7 mL
Articaine per 1.7 mL cartridge	68 mg
FDA reference product	Septocaine
U.S. sponsor	Septodont, Inc.
FDA approval	NDA 020971, approved in 2000
Preservative system	Sodium metabisulfite or related sulfite antioxidant
Regulatory category	Small-molecule drug
Biosimilar exposure	None

The high 4% concentration supports a compact cartridge and provides a commercially familiar product profile. It also increases the importance of osmolality, pH, local tolerability, and injection volume.

Which excipients are used in commercial articaine products?

Commercial articaine formulations generally use a small excipient system.

Sodium chloride

Sodium chloride adjusts tonicity. A properly controlled isotonic or near-isotonic formulation reduces injection discomfort and supports compatibility with dental tissue. The quantity must be balanced against the ionic contribution of articaine hydrochloride, epinephrine salts, and pH-adjusting agents.

Sodium chloride is inexpensive and presents minimal intellectual-property differentiation. Its commercial value lies in reproducible osmolality and manufacturing robustness rather than exclusivity.

Sodium metabisulfite

Sodium metabisulfite protects epinephrine from oxidation. Epinephrine is chemically unstable in aqueous solution and is sensitive to oxygen, light, elevated temperature, and alkaline conditions. The sulfite system is therefore central to shelf life and color control.[1]

Sulfites create a commercial tradeoff. They support epinephrine stability but can cause hypersensitivity reactions, particularly in susceptible patients with asthma. U.S. labeling for articaine with epinephrine includes a sulfite warning.[1]

This creates one of the clearest formulation opportunities: reducing sulfite exposure without sacrificing labeled potency, appearance, and shelf life.

Water for injection

Water for injection is the principal vehicle. Its microbial, endotoxin, and particulate controls are critical because dental cartridges are sterile parenteral products. Water quality is not a differentiating excipient, but it affects process capability and regulatory risk.

Hydrochloric acid or other pH adjusters

Articaine and epinephrine stability depends on pH control. Commercial products use acidification and buffer management to maintain a suitable pH range. Excessive buffering can increase ionic strength and affect tolerability, while insufficient control can accelerate epinephrine degradation.

A commercially valuable pH strategy is usually low-buffer or buffer-minimized design combined with oxygen control and optimized container closure.

What formulation patents protect articaine products?

Articaine's core composition is mature, and the primary commercial products are not generally dependent on a newly granted composition-of-matter patent. Protection is more likely to arise from formulation, packaging, manufacturing, device, or use claims.

Protection category	Relevance to articaine	Commercial assessment
Articaine molecule	Mature active ingredient	Low new-product exclusivity potential
Articaine hydrochloride salt	Established pharmaceutical form	Limited standalone differentiation
Articaine plus epinephrine	Established commercial combination	Formulation claims may be narrow
Sulfite-reduced formulation	Potentially valuable	Depends on stability and clinical equivalence
Oxygen-controlled cartridge	Potentially valuable	Stronger if linked to shelf-life data
Polymer or glass cartridge	Device and packaging opportunity	May support design-around barriers
Dual-chamber system	New delivery architecture	Higher development cost, stronger differentiation
Topical or sustained-release dosage form	Unoccupied commercial space	Requires new clinical and regulatory work
Manufacturing process	Potential trade-secret value	Difficult to enforce without disclosure

The practical patent strategy is to claim a complete product system rather than a single excipient. A stronger claim set could combine articaine concentration, epinephrine concentration, sulfite level, dissolved oxygen, pH, cartridge material, light transmission, and stability performance.

How strong is the patent estate for articaine?

The articaine patent estate is weaker at the active-ingredient level than the formulation and delivery opportunities. Articaine entered widespread dental use decades ago, and the FDA-approved reference product has passed its original approval-era exclusivity period.

Core composition protection

Core compound and salt claims are unlikely to provide meaningful exclusivity for a new articaine product. A company launching a conventional 4% articaine and epinephrine injection would compete primarily on regulatory approval, manufacturing cost, distribution, practitioner adoption, and supply reliability.

Formulation protection

Formulation patents can still be commercially relevant where they cover:

• Lower sulfite concentration with maintained epinephrine potency.
• Reduced dissolved oxygen.
• Improved color stability.
• Extended stability at controlled room temperature.
• Cartridge compositions that limit adsorption or extractables.
• Alternative antioxidants.
• Preservative-free or low-antioxidant products.
• Specific pH and osmolality ranges.
• Combination products with novel delivery devices.

The weakness is that many formulation claims can be vulnerable to obviousness challenges if they merely substitute a known antioxidant or adjust routine parameters. The strength improves when the formulation achieves an unexpected stability result, reduced injection pain, improved storage tolerance, or clinically meaningful sulfite reduction.

Manufacturing and trade-secret protection

Manufacturing know-how may be more defensible than broad formulation patents. Relevant trade secrets include:

• Nitrogen or inert-gas handling.
• Order of addition.
• Epinephrine incorporation conditions.
• Cartridge washing and depyrogenation.
• Light-protective filling operations.
• Control of dissolved oxygen.
• Stopper and plunger compatibility.
• Sterility assurance and terminal processing.

These measures can support a cost and quality advantage even where patent protection is limited.

What is the Orange Book status of articaine?

The U.S. reference product is Septocaine, articaine hydrochloride and epinephrine injection, associated with NDA 020971. The FDA label identifies the product as a dental injection supplied in 1.7 mL single-dose cartridges.[1]

FDA issue	Articaine status
Reference product	Septocaine
NDA	020971
Active ingredient	Articaine hydrochloride
Combination component	Epinephrine
Approved route	Infiltration and block injection for dental anesthesia
Exclusivity position	Original approval-era exclusivity expired
Biosimilar pathway	Not applicable
Orange Book relevance	Product-specific patent and exclusivity listings govern ANDA timing

A conventional generic would normally use an abbreviated pathway if it can demonstrate pharmaceutical equivalence, bioequivalence, quality, and compliance with applicable injectable-product requirements. Formulation changes that affect inactive ingredients, preservative systems, container closure, or stability can increase regulatory complexity.

When does articaine lose exclusivity?

Articaine's original U.S. regulatory exclusivity has expired. The remaining market barriers are primarily regulatory, manufacturing, commercial, and product-specific intellectual-property barriers.

Regulatory exclusivity

The original NDA approval occurred in 2000. The five-year new chemical entity exclusivity period and three-year approval-related exclusivity period are no longer active for the reference product.[1,3]

Patent exclusivity

A generic applicant must address any relevant patents listed for the reference product in the FDA Orange Book. The commercial significance of any listed patent depends on its claims, expiration date, and whether the applicant files a Paragraph IV certification.

A conventional articaine injection is unlikely to obtain meaningful new-chemical-entity protection. A differentiated product could seek patent protection for an improved formulation or delivery system, but those claims would be evaluated separately from the legacy articaine molecule.

Which companies are challenging or competing with articaine products?

Articaine competes in dental local anesthesia against lidocaine, mepivacaine, prilocaine, bupivacaine, and newer delivery technologies.

Product or class	Typical commercial position	Competitive issue
Septocaine	Established articaine reference brand	Strong dentist familiarity
Generic articaine/epinephrine	Price competition	Requires reliable sterile-cartridge supply
Lidocaine/epinephrine	Broad dental standard	Lower concentration and long clinical history
Mepivacaine	Useful where vasoconstrictor avoidance matters	Different duration and formulation profile
Prilocaine/felypressin products	Non-epinephrine alternative in some markets	Geographic and regulatory variation
Bupivacaine	Longer duration	Less suitable for routine short procedures
Computer-controlled delivery systems	Device-led differentiation	Higher capital and workflow requirements
Needle-free or topical systems	Patient-experience positioning	New clinical and regulatory requirements

Competition is fragmented by geography. Septodont has a strong articaine position in the United States and international dental markets, while Dentsply Sirona and regional manufacturers compete through dental anesthetic brands, distribution, and cartridge manufacturing.

What excipient strategies offer the strongest commercial opportunities?

Sulfite-reduced articaine

A lower-sulfite product is the clearest near-term opportunity. The formulation must preserve epinephrine concentration through shelf life while reducing sulfite exposure. A credible product would require:

• Quantified sulfite reduction.
• Epinephrine assay retention.
• Impurity control.
• Color stability.
• Photostability data.
• Container-closure oxygen performance.
• Real-time and accelerated stability.
• Clinical confirmation of injection tolerability where needed.

Possible approaches include tighter oxygen control, improved light protection, optimized pH, lower headspace oxygen, and alternative antioxidant systems.

Preservative-free articaine

Single-dose dental cartridges already have a strong basis for preservative minimization. A preservative-free or antioxidant-free articaine product would have commercial appeal if epinephrine stability can be achieved through packaging and manufacturing controls.

The main limitation is that removing sodium metabisulfite from an epinephrine-containing formulation can materially reduce stability. A product without epinephrine is technically simpler but competes against mepivacaine and other vasoconstrictor-free options.

Articaine without epinephrine

A vasoconstrictor-free articaine product could target patients in whom epinephrine is clinically undesirable or dentists seeking flexibility in short procedures. The commercial opportunity is less certain because the market already has established alternatives, including plain mepivacaine.

The differentiator would need to be a demonstrated benefit such as rapid onset, acceptable duration, low injection volume, or reduced cardiovascular concern. The absence of epinephrine also removes the need for sulfite antioxidant protection.

Improved cartridge packaging

Packaging is an underdeveloped differentiation area. Potential approaches include:

• Low-oxygen glass cartridges.
• Improved elastomer compatibility.
• High-barrier secondary packaging.
• Light-protective sleeves.
• Lower extractables and leachables.
• Tamper-evident dental cartridge systems.
• Prefilled delivery devices.

A packaging patent may have greater practical value when supported by comparative stability data against standard cartridges.

Alternative container materials

Glass remains common in dental cartridges, but polymer systems may provide lower breakage, improved manufacturing throughput, or compatibility with automated injection devices. Polymer migration, oxygen permeability, extractables, dimensional stability, and sterilization performance are the principal risks.

A polymer cartridge can create a differentiated product only if it improves total cost, safety, or delivery performance without compromising shelf life.

Modified concentrations

The standard 4% concentration is commercially entrenched. Lower concentrations could reduce total dose per cartridge but may require new clinical positioning and could weaken the perceived onset or performance advantage.

A lower-concentration product could target pediatric dentistry, geriatric patients, or procedures requiring reduced total articaine exposure. The opportunity depends on clinical data and dentist acceptance rather than excipient innovation alone.

What manufacturing barriers affect articaine commercialization?

The main manufacturing barrier is not synthesis of articaine. It is consistent production of a sterile, stable, low-particulate dental cartridge at scale.

Key control points include:

1. Epinephrine oxidation during compounding and filling.
2. Dissolved oxygen and headspace oxygen.
3. Sulfite assay and degradation products.
4. Cartridge glass delamination or breakage.
5. Elastomer compatibility.
6. Sterility and endotoxin control.
7. Fill-volume accuracy.
8. Light exposure during production and distribution.
9. Container-closure integrity.
10. Supply continuity for dental cartridges and components.

A manufacturer with existing sterile injectable infrastructure, dental distribution, and cartridge-filling capacity has a material advantage over a company that must build those capabilities from scratch.

What FDA pathway applies to an improved articaine formulation?

A conventional equivalent product would generally pursue an ANDA, subject to FDA requirements for pharmaceutical equivalence, bioequivalence, inactive ingredients, manufacturing, and container closure.[3]

A materially different formulation may require a 505(b)(2) application. This pathway may be relevant for:

• Novel antioxidant systems.
• New concentrations.
• New container materials.
• Extended stability claims.
• New delivery devices.
• New routes or dosage forms.
• New clinical claims.

A 505(b)(2) strategy can support formulation differentiation, but it normally requires a stronger evidence package than a conventional generic. Excipients with prior parenteral use may reduce development risk, while novel excipients can create toxicology and regulatory complications.

What Paragraph IV challenges and generic launch risks exist?

A Paragraph IV challenge would be relevant only if an applicant certifies that a listed patent is invalid, unenforceable, or not infringed. For a mature articaine reference product, the commercial case for a Paragraph IV filing depends on whether the Orange Book contains enforceable formulation, method-of-use, or device-related patents.

Launch scenario	Timing	Risk profile
Conventional generic after patent clearance	Earliest legally available date	Price erosion and supply competition
Paragraph IV launch	Potentially earlier than patent expiry	Litigation, injunction, damages exposure
505(b)(2) improved formulation	After approval and applicable exclusivity	Clinical and formulation-development risk
Sulfite-reduced product	Dependent on stability and regulatory pathway	Differentiation may support premium pricing
Device-integrated articaine	After device and drug approval	Higher development and adoption risk
Vasoconstrictor-free articaine	After new clinical positioning	Direct competition from mepivacaine

A generic launch could produce rapid price compression if several suppliers enter simultaneously. Dental anesthetic shortages and distributor concentration can moderate that pressure, particularly when a supplier offers dependable cartridge availability.

What licensing deals could create value in articaine?

The most attractive licensing targets are formulation and delivery technologies rather than articaine chemistry.

Potential deal structures include:

• Licensing a low-sulfite antioxidant platform.
• Acquiring a high-barrier dental cartridge technology.
• Partnering with a sterile injectable manufacturer.
• Licensing a computer-controlled injection device.
• Combining articaine with a long-acting or adjunctive dental formulation.
• Regional licensing for markets where articaine penetration remains lower.
• Co-development with dental-service organizations or distribution networks.

A formulation license should be assessed against three commercial tests: measurable stability improvement, regulatory pathway clarity, and manufacturing compatibility with existing cartridge lines.

How does articaine compare with lidocaine on excipient and commercial strategy?

Articaine has a stronger opportunity for premium formulation positioning because its leading product is concentrated at 4% and commonly includes epinephrine. Lidocaine has a broader generic base and more established formulation diversity.

Factor	Articaine	Lidocaine
Core market position	Dental-focused	Broad local-anesthetic market
Common dental strength	4%	2%
Formulation differentiation	Cartridge stability and sulfite reduction	Broad dosage-form and concentration range
Generic pressure	Increasing	High
Premium opportunity	Dental workflow and packaging	Specialized delivery or combination products
Biosimilar risk	None	None
Manufacturing complexity	Sterile cartridge and epinephrine stability	Varies by product
Clinical switching barrier	Dentist familiarity	Extensive established use

Articaine is better suited to a focused dental product strategy. Lidocaine is better suited to high-volume generic scale and diversified dosage forms.

What revenue exposure does articaine create?

Articaine revenue is concentrated in dental procedures, distributors, and professional-use channels. Commercial exposure depends on unit volume, cartridge pricing, reimbursement practices, and dentist preference rather than chronic prescription retention.

The strongest revenue opportunities are:

• Premium pricing for supply reliability.
• Private-label dental anesthetics.
• Regional generic entry.
• Low-sulfite positioning.
• Integrated cartridge-and-device systems.
• Contract manufacturing for dental suppliers.
• Portfolio bundling with needles, syringes, and dental consumables.

The largest downside risk is rapid commoditization after multiple generic entrants. A product without a formulation, packaging, device, or supply-chain advantage is likely to compete mainly on price.

Key Takeaways

• Articaine is a mature small-molecule dental anesthetic with expired original regulatory exclusivity.
• The commercial formulation is typically 4% articaine hydrochloride with epinephrine, sodium chloride, sodium metabisulfite, water for injection, and pH control.
• Sulfite reduction is the most credible excipient-led opportunity.
• Oxygen management, light protection, and cartridge design may create stronger value than simple excipient substitution.
• Conventional articaine products are likely to face generic price competition.
• A differentiated 505(b)(2) product could pursue new stability, packaging, concentration, or delivery claims.
• Biosimilar risk is not relevant because articaine is a chemically synthesized small molecule.
• Patent value is more likely in formulation, packaging, device, and manufacturing claims than in the active ingredient.
• Reliable sterile-cartridge manufacturing and dental distribution are major competitive barriers.
• Licensing opportunities are strongest in antioxidant systems, high-barrier cartridges, delivery devices, and regional commercialization.

FAQs

Can articaine be formulated without sodium metabisulfite?

Yes, but removing sodium metabisulfite is more practical in a vasoconstrictor-free product. In epinephrine-containing articaine, the formulation must replace or compensate for sulfite protection through antioxidant selection, oxygen control, packaging, and validated stability.

Is a 4% articaine formulation automatically therapeutically equivalent to Septocaine?

No. Strength alone does not establish equivalence. The applicant must address active-ingredient content, epinephrine content, excipients, impurities, sterility, container closure, stability, and applicable FDA requirements.

Can a new articaine cartridge receive patent protection?

Yes. Patentable subject matter may include cartridge materials, oxygen-control systems, stability-enhancing excipient combinations, specific pH and sulfite ranges, and integrated delivery devices. The claims must satisfy novelty, nonobviousness, enablement, and written-description requirements.

Is articaine suitable for a sustained-release dental formulation?

Potentially, but the product would require new formulation, local-tissue safety, pharmacokinetic, and clinical development. Sustained release could create a stronger commercial position than another conventional aqueous cartridge.

What is the best commercial entry strategy for a new articaine manufacturer?

The lowest-risk strategy is a conventional sterile cartridge product supported by reliable supply and competitive pricing. The higher-value strategy is a differentiated formulation, such as sulfite-reduced articaine with validated shelf life and packaging claims, supported by a 505(b)(2) or other appropriate regulatory pathway.

References

1. U.S. Food and Drug Administration. (2023). Septocaine: Articaine hydrochloride and epinephrine injection prescribing information.
2. Malamed, S. F. (2019). Handbook of local anesthesia (7th ed.). Elsevier.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
4. U.S. Food and Drug Administration. (2017). Abbreviated new drug application approvals: Regulatory requirements for generic drug products. FDA.
5. European Medicines Agency. (2019). Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container. EMA.